GlycoMira Therapeutics Receives Key Patent for First-in-Class Oncology Therapeutic
Key patent covering GlycoMira's lead compound GM-1111 adds to the Company's already strong IP portfolio. - November 04, 2024
Press Releases 1 - 1 of 1
Key patent covering GlycoMira's lead compound GM-1111 adds to the Company's already strong IP portfolio. - November 04, 2024